In 2016, the Annals of Surgical Oncology published the results of the National Cancer Institute (NCI) Sponsored study ACOSOG (Alliance) Z1072 Phase II, single arm non-randomized study in the treatment of invasive breast disease. This study evaluated the rate of complete tumor ablation. The Visica® 2 Treatment System was the exclusive device used in this landmark study.
- Patients were treated with cryoablation
- Eligible patients included those with univocal invasive ductal breast cancer ≤2.0 cm, with <25% intraductal component and tumor enhancement on MRI
- A total of 19 centers contributed 99 patients, of which 86 patients (87 breast cancers) were evaluable for data analysis
- 100% ablation in all tumors <1.0 cm in size, defined as no remaining invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS) on pathological examination of the tumor
- Cryoablation was effective in 92% of all targeted tumors
- No cases were categorized as ineffective ablation within the cryoablation zone (all cancer cells within the treatment zone were killed)
To review the Z1072 abstract, please click here
Current Clinical Study: FROST
Sanarus Technologies is sponsoring a multi-center clinical study (FROST), A Study of Cryoablation in the Management of Early Stage Breast Cancer, for patients who prefer an alternative to surgery. This is a phase II clinical study of Z1072. To learn more about the FROST clinical study, please click here.
Where to learn more
For more information about clinical trials, visit: Understanding Clinical Trials